Results 61 to 70 of about 1,093,493 (290)

Risk Factors that Impact Treatment with Oral Janus Kinase Inhibitors Among Adult Patients with Atopic Dermatitis: A Nationwide Registry Study

Acta Dermato-Venereologica
The European Medicines Agency recently limited the use of oral Janus kinase inhibitors in certain patient populations, including those with atopic dermatitis.
Ida Vittrup, David Thein, Simon Francis Thomsen, Alexander Egeberg, Jacob P. Thyssen   +4 more
doaj   +1 more source

Structural Variants in the Human Genome Associated With Gut Microbiome and Blood Metabolic Traits With Potential Causal Links

Advanced Science, EarlyView.
Based on a multi‐omics cohort of 2002 individuals comprising high‐depth whole‐genome and metagenomic sequencing data, blood metabolites, and detailed questionnaires, we identified 138 859 high‐confidence SVs, uncovering 36 significant SV–microbiome associations and 48 SV–blood metabolite associations.
Qun Zhou, Keqing Wang, Junhong Chen, Haoyu Wang, Xinjiang Tan, Xuanlin Huang, Zhiyin Lin, Xun Xu, Xin Jin, Shaoqiao Zhang, Liang Xiao, Yuanqiang Zou, Tao Zhang, Xiaomin Liu   +13 more
wiley   +1 more source

[Janus kinase inhibitors for the treatment of atopic dermatitis-evaluation of current data and practical experience].

, 2022
BACKGROUND: Atopic dermatitis is a common chronic inflammatory skin disease and has a major impact on patient's quality of life. Janus kinase inhibitors were recently approved for the treatment of atopic dermatitis.
Lauffer, Felix;Biedermann, Tilo
core   +1 more source

Advancing Biotherapeutic Treatment of Ulcerative Colitis Using Lipid Mesophases: Formulation Design and Preclinical Validation

Advanced Science, EarlyView.
Lipid mesophases provide a versatile platform for colon‐targeted delivery of biotherapeutics, protecting them from degradation while enhancing mucoadhesion and enabling localized, controlled release to the inflamed mucosa after oral or rectal administration. In a DSS‐induced colitis model, this strategy reduced disease activity, inflammatory biomarkers,
Rafaela Gazzi, Tiziana Cremona, Reto Czekalla, Emily Campbell, Marlene Schwarzfischer, Doris Pöhlmann, Vanessa Dobernig, Gerhard Rogler, Michael Scharl, Alessandra Bergadano, Raffaele Mezzenga, Martin Kuentz, Paola Luciani, Simone Aleandri   +13 more
wiley   +1 more source

RBMS1 Contributes to Early Arteriovenous Fistula Neointimal Remodeling Through Modulation of VSMC Phenotypic Responses

Advanced Science, EarlyView.
Postoperative arteriovenous fistulas exhibit increased RBMS1 in vascular smooth muscle cells (VSMCs). In experimental AVFs, RBMS1 overexpression aggravates, whereas deletion attenuates, neointimal hyperplasia. RBMS1 binds MPZL1 mRNA and promotes exon 5 skipping to generate MPZL1‐Δ5, which interacts with G3BP1 to activate AKT, driving VSMC proliferation,
Zongda Li, Chengwei Zhang, Xinying Yu, Shuang Yao, Yiting Lai, Xiaozhu Sun, Yao Zhao, Xiaoyu Lan, Tingting Hu, Wenjin Li, Zhenzhen Ma, Huimin Ma, Zihan Wang, Haihai Liang, Jundong Jiao   +14 more
wiley   +1 more source

Essential Updates in the Surgical Management of Inflammatory Bowel Disease: Current Topics From 2024 to Mid‐2026

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Inflammatory bowel disease management has undergone a major transformation with the introduction of treat‐to‐target strategies and highly effective biologic and small‐molecule therapies. Although these advances have reduced the overall requirement for surgery, operative intervention remains essential for selected patients with ulcerative ...
Yoshiki Okita, Tadanobu Shimura, Mikio Kawamura, Yuhki Koike, Yuji Toiyama   +4 more
wiley   +1 more source

Modern Management Approaches for Alopecia Areata

Вопросы современной педиатрии
Alopecia areata is a chronic genetically determined inflammatory autoimmune disease damaging hair follicles and leading to temporary or persistent nonscarring hair loss.
Eduard T. Ambarchyan, Vladislav V. Ivanchikov, Anastasiya D. Alekseeva, Olga B. Gordeeva, Leyla S. Namazova-Baranova   +4 more
doaj   +1 more source

Outcomes of Tapering Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: A Multicenter Randomized Non‐Inferiority Trial

Arthritis &Rheumatology, Accepted Article.
Objective Evidence supporting tapering of biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) in rheumatoid arthritis (RA) patients with sustained low disease activity (LDA) remains limited. We evaluated the efficacy and safety of a structured b/tsDMARD tapering strategy in patients with RA who had achieved sustained LDA ...
Dong‐Jin Park, Sung‐Eun Choi, Ji‐Hyoun Kang, Jung‐Yoon Choe, Hye‐Soon Lee, So‐Young Bang, Yun‐Hong Cheon, Sang‐Il Lee, Mingyo Kim, Yoon‐Kyoung Sung, Soo‐Kyung Cho, Jae Hyun Jung, Sung Hae Chang, Sung Won Lee, Yeon‐Ah Lee, Seung‐Geun Lee, Hyun‐Sook Kim, Seung‐Ki Kwok, Seung‐Cheol Shim, Shin‐Seok Lee   +19 more
wiley   +1 more source

Janus Kinase Deregulation in Leukemia and Lymphoma [PDF]

, 2012
Genetic alterations affecting members of the Janus kinase (JAK) family have been discovered in a wide array of cancers and are particularly prominent in hematological malignancies.
Chen, Edwin, Staudt, L.M., Green, Anthony R., Staudt, Louis M., Chen, E., Green, A.R.   +5 more
core   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source